Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 181 to 188 of 188 results for enzymes

  1. Thousands could benefit from treatment for severe alopecia

    New one-a-day tablet for people with severe hair loss due to alopecia areata recommended by NICE

  2. New treatment to increase successful kidney transplants

    A new treatment that increases the chance of a successful kidney transplant has been recommended by NICE in final draft guidance.

  3. First gene therapy for rare genetic neurodegenerative disorder in children, recommended in NICE draft guidance

    Children with a rare, fatal, genetic disorder will be able to benefit from a new one-off treatment under new NICE guidance.

  4. Heart failure: 4 pillars (HFrEF) (IND317)

    This indicator covers the the percentage of patients with a current diagnosis of heart failure with reduced ejection fraction, who are currently treated with an angiotensin-converting enzyme inhibitor or angiotensin receptor-neprilysin inhibitor or angiotensin II receptor blocker, a beta blocker, a mineralocorticoid receptor antagonist and a sodium glucose co-transporter-2 inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  5. New clot-busting drug recommended by NICE set to save NHS £millions

    Giving a new clot-busting drug to people who have had a stroke could help save the NHS millions of pounds.

  6. NICE recommends first treatment for rare blood disorder

    People with a rare blood disorder have access to a new treatment following draft guidance from NICE.

  7. NICE recommends innovative treatment for severe blood disorder for NHS use

    Caplacizumab, with plasma exchange and immunosuppression, will be used to treat acute acquired thrombotic thrombocytopenic purpura.

  8. NICE recommends olaparib for early breast cancer and metastatic prostate cancer

    Deals for anti-cancer medicine olaparib have paved the way for hundreds to benefit as NICE recommends it for some types of early breast cancer and advanced prostate cancer.